Adage Capital Partners Gp, L.L.C. Cabaletta Bio, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$51.6 Billion
Q1 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,634,473 shares of CABA stock, worth $5.09 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,634,473

Previous 3,634,473 -0.0%

Holding current value

$5.09 Million

Previous $8 Million 36.82%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.87 - $4.91 $1.12 Million - $2.94 Million	597,828 Added 19.69%	3,634,473 $8 Million
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $3.86 Million - $5.84 Million	-230,000 Reduced 7.04%	3,036,645 $51.8 Million
Q2 2023 Aug 14, 2023	BUY	$7.65 - $13.95 $5.55 Million - $10.1 Million	725,000 Added 28.52%	3,266,645 $42.2 Million
Q4 2021 Feb 14, 2022	SELL	$3.36 - $14.64 $1.68 Million - $7.32 Million	-500,000 Reduced 16.44%	2,541,645 $9.63 Million
Q1 2021 May 17, 2021	SELL	$10.39 - $14.53 $1.45 Million - $2.02 Million	-139,160 Reduced 4.37%	3,041,645 $33.8 Million
Q4 2020 Feb 16, 2021	SELL	$9.81 - $15.8 $2.2 Million - $3.54 Million	-223,955 Reduced 6.58%	3,180,805 $39.7 Million
Q3 2020 Nov 16, 2020	SELL	$9.71 - $14.41 $1.56 Million - $2.31 Million	-160,249 Reduced 4.5%	3,404,760 $36.9 Million
Q2 2020 Aug 14, 2020	SELL	$6.39 - $11.28 $254,008 - $448,391	-39,751 Reduced 1.1%	3,565,009 $39.7 Million
Q1 2020 May 15, 2020	SELL	$6.0 - $18.67 $822,996 - $2.56 Million	-137,166 Reduced 3.67%	3,604,760 $26.3 Million
Q4 2019 Feb 14, 2020	BUY	$7.88 - $17.71 $29.5 Million - $66.3 Million	3,741,926 New	3,741,926 $52.3 Million

Others Institutions Holding CABA

# of Institutions

Shares Held

40.5M

Call Options Held

154K

Put Options Held

192K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $40.6M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Cabaletta Bio, Inc. Transaction History